2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

JUNTEN BIO Co., Ltd.

Company Presentations

Thursday, July 23 Company Presentations 3–Japan

JUNTEN BIO Co., Ltd.

Company Info

Name /JUNTEN BIO Co., Ltd.

Address /Urbannet Nihonbashi 2-chome Building 10F, 2-1-3 Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan

Website /juntenbio.co.jp/about-us/

Presenter

Name /Yui Maehara

Title /Manager

Email /maehara@juntenbio.co.jp

Telephone /(Work) 81-3-5812-4757

Fax /

Mobile /

Company Type

Biotechnology

About the Company

JUNTEN BIO is a start-up, clinical-stage Japanese company founded in June 2018, with its property licensed from Juntendo University.

We are researching and developing next-generation transplant technology.

Since we obtained remarkable clinical research data, we’re starting phase 1/2 clinical trial for a liver transplant in Japan this month.

Brief Description of main products or services

For patients with end-stage liver or kidney disease, an organ transplant provides the chance to regain many aspects of a normal life.

After the transplant, patients have to take several immunosuppressive drugs every day for life long period to avoid potential infections for as long as they are taking immunosuppressive therapy.

To solve the problems, some solutions like less side effect immunosuppressant or Personalized treatment using immune markers as indicators are developing. We strongly believe that our Induced T cells with suppressing function (JB-101) can achieve transplant tolerance. Inducing tolerance in a transplant recipient would eliminate the need for chronic immunosuppressants and restore the long-term quality of life to recipients. Also, reduction of the immunosuppressant usage highly contributes healthcare economy.

In Japan, we are just starting Phase1/2 clinical trial this month.

In the US, we are supposed to have FDA pre-IND consultation this year.

In addition to this transplant area, we have already confirmed our technology platform can produced T cells to specifically suppress various antigen such as self-antigen or food peptide and so on. So that our next targets are ES or IPS cells, autoimmune disease and allergic disease.

Contact Person

Name /Yui Maehara

Email /maehara@juntenbio.co.jp

Phone /(Work) 81-3-5812-4757